LOGIN 

 

JOIN

 

RENEW

 

CME/MOC

ATS Governance

HomeAboutATS Governance ▶ ATS Leadership
ATS Leadership

Gregory P. Downey

Gregory Downey, MD, ATSF, originally elected in 2019, will serve as the President.

Dr. Downey is a professor of medicine, pediatrics, and immunology and genomic medicine at National Jewish Health where he also serves as executive vice president of Academic Affairs, and provost. He is also professor of medicine and immunology and microbiology and associate dean of Health Affairs at the University of Colorado in Denver.

2022 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities:  Dr. Downey has served on the Board of Directors of the Lovelace Respiratory Institute and as a consultant for Angion in the development of novel anti-fibrotic compounds. No payments have been received from Angion. He previously served as a consultant for Biomotiv in the development of novel anti-inflammatory compounds. He served as a consultant for Altimmune for antiviral therapies. Dr. Downey served as a consultant for Translate Bio for ARDS treatment.

 

M. Patricia Rivera

M. Patricia Rivera, MD, ATSF, originally elected in 2020, will serve as the President-Elect. Dr. Rivera will serve as President in 2023-2024.

Dr. Rivera is the C. Jane Davis & C. Robert Davis Distinguished Professor in Pulmonary Medicine, as well as chief, Division of Pulmonary and Critical Care Medicine at the University of Rochester Medical Center. She also serves as adjunct professor of Medicine at the University of North Carolina at Chapel Hill, and the co-director of the North Carolina Lung Screening Registry. Dr. Rivera originally founded the Multidisciplinary Lung Cancer Screening Program at UNC.

2022 Disclosure of Potential Conflicts of Interest Relevant to ATS Activities: Dr. Rivera conducts research supported by the National Institutes of Health focused on comorbidity and functional status of persons undergoing lung cancer screening. She serves as a consultant for American Board of Internal Medicine for pulmonary boards writing committee.

 

 Irina Petrache, MD, ATSF

Irina Petrache, MD, ATSF, elected in 2021, will serve as the Secretary. Dr. Petrache will serve as President in 2024-2025.

Dr. Petrache is professor of Medicine at the University of Colorado. She also serves as chief of  Pulmonary, Critical Care and Sleep Medicine, associate vice president of Faculty Development, and Wollowick Chair in COPD Research & Professor of Medicine at National Jewish Health.

2022 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Petrache is a scientific co-founder of Allinaire Therapeutics which develops novel therapeutics for pulmonary arterial hypertension (PAH) and other pulmonary diseases, including EMAP II.  She has conducted research supported by Allinaire, which evolved from work of Dr. Petrache and colleagues as part of the University of Indiana Center for Biomedical Innovation and is funded by Biomotiv. She served as a consultant for Ceramedix for antibody therapies. She has participated in National Institutes of Health-supported research on sphingolipids and the effect of vaping on lung parenchyma.

 

Jesse Roman, MD

Jesse Roman, MD, originally elected in 2022, will serve as the ATS Treasurer through 2025.

Dr. Roman has been a member of the ATS since 1988, and he is committed to diversity, equity and inclusion, having served as a founding leader of the Health Equity Subcommittee within the Health Equity and Diversity Committee. He is currently with Jefferson Health in Philadelphia, Pa, where he serves as the Ludwig Kind Professor of Medicine; enterprise division chief, Pulmonary, Allergy and Critical Care Medicine; and director of the Pulmonary and Critical Care Medicine Fellowship Program. Dr. Roman also serves as CEO of the Jane & Leonard Korman Respiratory Institute of Jefferson Health and National Jewish Health.

2022 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Roman has served on a data safety and monitoring board for Novartis for anti-fibrotic treatment. He has received industry-sponsored research support to his institution for anti-fibrotic treatment from F. Hoffmann-LaRoche, Horizon Therapeutics, Galapagos, Syneos Health, Boehringer Ingelheim, Bellerophon Therapeutics, Fibrogen. He has served as a consultant for Boehringer Ingelheim developing national registry designed to obtain real life data about interstitial lung disorders.

 

Lynn Schnapp, MD

Lynn Schnapp, MD, ATSF, originally elected in 2018, will serve as the Immediate Past-President.

Dr. Schnapp is the George R. and Elaine Love professor and chair of the Department of Medicine at the University of Wisconsin School of Medicine and Public Health. She is a faculty member in the division of Allergy, Pulmonary and Critical Care Medicine.

2022 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Schnapp has participated in research studies supported by BMS and Ironwood, with funding received by her institution. She has contributed to publications of Elsevier, Springer, and UpToDate, with payments from Elsevier and Springer received directly and payments from UpToDate received by her institution. Her ongoing supported research is focused on understanding the roles of pericytes in the immune response and fibrotic response in the lung.